medigraphic.com
Órgano Oficial del Instituto de Ciencias de la Salud, Hospital Escuela y Facultad de Medicina-Xalapa

2006, Number 2

<< Back Next >>

Rev Med UV 2006; 6 (2)

Antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum

Solís MR, Vázquez CT, Celis S, Hernández CL

Language: Spanish
References: 29
Page: 11-17
PDF size: 541.24 Kb.


ABSTRACT

Mycoplasma hominis (Mh) and Ureaplasma urealyticum (Uu) represent important pathogens associated to genital and urinary tract infections as well as to obstetric pathologies and infertility. In this piece of work it is proposed the study of the susceptibility of these microorganisms to seven antibiotics. A total of 156 samples, positive to Mh and/or Uu of cervicovaginal and urethral exudates were evaluated for susceptibility to Roxithromycin, Azithromycin, Josamycin, Minocycline, Doxycycline, Ofloxacin and Norfloxacin. Mycoplasma hominis was detected in fourteen samples (9%), Ureaplasma urealyticum in 83 samples (53%) and 59 were positive for both (38%). The resistance of Mycoplasma hominis to Josamycin, Roxithromycin, Minocycline and Doxycycline was of 28.57%, 28.57%, 7.14% and 0% respectively. The resistance of Ureaplasma urealyticum to Josamycin, Norfloxacin, Doxycycline, Minocycline and Azithromycin was of 27.7%, 25.3%, 12.05%, 10.84% and 7.23% respectively. The mixed isolations displayed susceptibility to Doxycycline and Minocycline with resistance percentages of 28.8 and 30.51 and a greater resistance to Roxithromycin 86.44%, Josamycin 67.80%, Norfloxacin 67.80%, 62.71% Azithromycin and Ofloxacin 57.63%. It is important to point out that in the clinical practice is uncommon to ask for the identification of these microorganisms, so before initiating an antimicrobial treatment for any one of them, it is of high-priority to consider the susceptibility of that pathogen, being the increase in the resistance to the antibiotics due to the increase in the excessive and uncontrolled usage of them and to the propagation of the bacteria that are resistant to them.


REFERENCES

  1. Dienes L. and G. Edsall. Observations on the Lorganism of Klieneberger. Proc. Soc Exp. Biol. Med. 1937. 36: 740-744.

  2. Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev. 2005.Oct; 18(4): 757-89. Review.

  3. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother. 2001. Sep; 45(9): 2604-8.

  4. Taylor-Robinson D, McCormack WM. The genital mycoplasmas. N Engl J Med. 1980. May 8; 302(19): 1063-7. Review.

  5. Mardh PA. Mycoplasma hominis - a neglected human pathogen. Eur J Clin Microbiol. 1983. Aug; 2(4): 303-8. Review. No abstract available.

  6. Plummer DC, Garland SM, Gulbert GL. Bacteraemia and pelvic infection in women due to Ureaplasma urealyticum and Mycoplasma hominis. Med J Aust. 1987. Feb 2; 146(3): 135-7.

  7. Grenabo L, H Hedelin, and S Pettersson. Urinary infection stones caused by Ureaplasma urealyticum: a review. Scand. J. Infect Dis Suppl. 1988. 53: 46- 49.

  8. Schimke RT, Barile MF. Arginine metabolism in pleuropneumonia-like organisms isolated from mammalian cell culture. J Bacteriol. 1963. Aug; 86: 195-206.

  9. Ligon JV, Kenny GE. Virulence of ureaplasmal urease for mice. Infect Immun. 1991. Mar; 59(3): 1170-1.

  10. Kenny GE, Hooton TM, Roberts MC, Cartwright FD, Hoyt J. Susceptibilities of genital Mycoplasmas to the newer quinolones as determined by the agar dilution method. Antimicrob Agents Chemother. 1989. Jan; 33(1): 103-7.

  11. Arai S, Gohara Y, Kuwano K, Kawashima T. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides Mycoplasma pneumoniae against Antimicrob Agents. Chemother. 1992. Jun; 36(6): 1322-4.

  12. Hannan PC. Comparative susceptibilities of various AIDS-associated and human urogenital tract Mycoplasmas and strains of Mycoplasma pneumoniae to 10 classes of antimicrobial agent in vitro. J Med Microbiol. 1998. Dec; 47(12): 1115-22.

  13. Roberts MC, Koutsky LA, Holmes KK, LeBlanc DJ, Kenny GE. Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences.Antimicrob. Agents Chemother. 1985. Jul; 28(1): 141-3.

  14. Roberts MC and Kenny GE. Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum. Antimicrobial Agents and Chemotherapy. 1986. 40, 551-9.

  15. Leng Z, Riley DE, Berger RE, Krieger JN, Roberts MC. Distribution and mobility of the tetracycline resistance determinant tetQ. J Antimicrob Chemother. 1997. Oct; 40(4): 551-9.

  16. Fagundo R, Sánchez A, Jáuregui J. Comportamiento antimicrobiano de aislamientos clínicos de Mycoplasma hominis y ureaplasma urealyticum así como la evolución de su resistencia en un periodo de cinco años. Labciencia. 2006. Mayo 14(2).

  17. Bebear C, de Barbeyrac B, Dewilde A, Edert D, Janvresse C, Layani MP, Le Faou A, Lefevre JC, Mendel I, Renaudin H, et al. Multicenter study of the in vitro sensitivity of genital Mycoplasmas to antibiotics. Pathol Biol (Paris). 1993 Apr; 41(4): 289-93.

  18. Ramírez C, Casanova G, Menoca G; Ortiz, F ; Ahued R. Prevalencia de la infección cervicovaginal por Micoplasma hominis y Ureaplasma urealyticum en pacientes ginecológicas del Instituto Nacional de Perinatología. Enf. Inf y Microbiología. 2004. 24(1), enero-marzo.

  19. Narcio Reyes ML, Solórzano Santos F, Arredondo García JL, Calderón Jaimes E, Beltrán Zúniga M. Etiology of cervicovaginal infection in pregnant and non-pregnant patients. Ginecol Obstet Mex. 1989 Feb; 57: 41-6.

  20. Rivera JA, Centeno TM, Santellan OM, Rodríguez PN Prevalencia de Ureaplasma urealyticum en mujeres. Rev Mex Patol Clin 2004; 51(1): 33-36.

  21. Zuo CX, Huang JH, Chen J, Lu JY, Xiang YP. Female urogenital mycoplasma infection and drug sensitivity status in Changsha. Nan Fang Yi Ke Da Xue Xue Bao. 2006 Jun; 26(6): 831-2, 836.

  22. Karabay O, Topcuoglu A, Kocoglu E, Gurel S, Gurel H, Ince NK. Prevalence and antibiotic susceptibility of genital Mycoplasma hominis and Ureaplasma urealyticum in a university hospital in Turkey. Clin Exp Obstet Gynecol. 2006; 33(1): 36-8.

  23. Samra Z, Soffer Y, Pansky M. Prevalence of genital Chlamydia and Mycoplasma infection in couples attending a male infertility clinic. Eur J Epidemiol. 1994 Feb; 10(1): 69-73.

  24. Guo X, Ye Z, Deng R. Male urogenital tract mycoplasma infection and drug-resistance evolution. Zhonghua Nan Ke Xue. 2004 Feb; 10(2): 122-4.

  25. Huang C, Liu Z, Lin N, Tu Y, Li J, Zhang D. Susceptibility of mixed infection of Ureaplasma Urealyticum and Mycoplasma Hominis to seven antimicrobial agents and comparison with that of Ureaplasma Urealyticum infection. J Huazhong Univ Sci Technolog Med Sci. 2003; 23(2): 203-5.

  26. Krausse R, Ullmann U. Comparative in vitro activity of fleroxacin (RO 23-6240) against Ureaplasma urealyticum and Mycoplasma hominis. Eur J Clin Microbiol Infect Dis. 1988 Feb; 7(1): 67-9.

  27. Centers for disease control and prevention. Diseases characterized by urethritis and cervicitis. Sexually transmitted diseases treatment guidelines. Morbidity mortality weekly. Report. 2002. Vol 15 (No RR-6), 30-42.

  28. Falk L, Fredlund H, Jensen JS. Tetracycline treatment does not eradicate Mycoplasma genitalium. Sex Transm Infect. 2003 Aug; 79(4): 318-9.




2020     |     www.medigraphic.com